See more : Dermapharm Holding SE (DMPHF) Income Statement Analysis – Financial Results
Complete financial analysis of Aldeyra Therapeutics, Inc. (ALDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aldeyra Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Teleperformance SE (TLPFY) Income Statement Analysis – Financial Results
- PT Utama Radar Cahaya Tbk (RCCC.JK) Income Statement Analysis – Financial Results
- Ning Xia Yin Xing Energy Co.,Ltd (000862.SZ) Income Statement Analysis – Financial Results
- Grand Fortune High Grade Limited (GFHG.L) Income Statement Analysis – Financial Results
- Hawesko Holding AG (HAW.DE) Income Statement Analysis – Financial Results
Aldeyra Therapeutics, Inc. (ALDX)
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -262.78K | -258.71K | -264.18K | -56.22K | -96.31K | -71.00K | -37.85K | -35.79K | -18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.46M | 47.31M | 44.94M | 24.68M | 44.35M | 29.82M | 16.30M | 13.18M | 7.57M | 3.71M | 1.54M | 469.27K | 1.36M |
| General & Administrative | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.33M | 720.79K | -21.48M | 5.41K |
| Operating Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Cost & Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Interest Income | 7.32M | 2.35M | 185.36K | 292.22K | 1.54M | 952.70K | 261.25K | 102.04K | 11.13K | 3.00 | 31.00 | 101.00 | 5.00K |
| Interest Expense | 2.07M | 1.69M | 1.74M | 1.90M | 603.85K | 146.79K | 113.45K | 105.51K | 112.31K | 244.17K | 159.32K | 342.01K | 279.93K |
| Depreciation & Amortization | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 1.07K | 31.00 | 3.74K | 1.59K |
| EBITDA | -35.21M | -60.07M | -55.77M | -36.07M | -61.44M | -38.68M | -22.19M | -18.56M | -11.96M | -4.94M | 13.22M | -22.73M | -2.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.79M | -62.68M | -56.22M | -36.42M | -63.07M | -39.70M | -22.49M | -18.70M | -11.99M | -7.27M | -3.68M | -1.11M | -2.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.25M | 655.35K | -1.56M | -3.37M | -5.63M | 805.91K | 147.80K | -3.47K | -101.18K | 2.08M | 16.74M | -21.96M | -269.53K |
| Income Before Tax | -37.54M | -62.02M | -57.78M | -38.03M | -62.14M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -655.35K | 1.48M | -479.27K | -1.31M | 952.70K | 223.40K | 66.25K | -7.65K | 243.11K | 159.29K | -21.14M | 285.34K |
| Net Income | -37.54M | -61.37M | -59.25M | -37.55M | -60.83M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 | 39.90 | -5.72 | -7.26 |
| EPS Diluted | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.35 | 2.72 | -5.10 | -0.50 |
| Weighted Avg Shares Out | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 327.37K | 4.04M | 327.37K |
| Weighted Avg Shares Out (Dil) | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 4.80M | 4.52M | 4.80M |
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
5 Most Active Penny Stocks Today & Why They're Moving Now
Why Are Stocks Up Today?
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive' issues with NDA for dry-eye disease treatment
Aldeyra Therapeutics stock tanks on warning that FDA will reject new drug application
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX
Source: https://incomestatements.info
Category: Stock Reports